Towards Molecular Diagnosis and Targeted Therapy of Lymphoid Malignancies

Seminars in Hematology

Volumn 40, Issue 4, 2003, Pages 296-307

  Wiestner, Adrian ^b   Staudt, Louis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC PROCEDURE; DRUG TARGETING; GENE; GENE EXPRESSION PROFILING; HUMAN; LYMPHATIC SYSTEM TUMOR; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; ZAP 70 GENE;

EID: 0142126182     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(03)00194-X     Document Type: Article

References (80)

1. Adams J: Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6:493-500, 2002
2. Aisenberg AC: Historical review of lymphomas. Br J Haematol 109:466-476, 2000
3. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
4. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997
5. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107:241-246, 2001
6. Barista I, Romaguera JE, Cabanillas F: Mantle-cell lymphoma. Lancet Oncol 2:141-148, 2001
7. Bea S, Tort F, Pinyol M, et al: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409-2412, 2001
8. Borche L, Lim A, Binet JL, et al: Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 76:562-569, 1990
9. Bosch F, Lopez-Guillermo A, Campo E. et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998
10. Caligaris-Cappio F: B-chronic lymphocytic leukemia: A malignancy of anti-self B cells. Blood 87:2615-2620, 1996
11. Chen L, Widhopf G, Huynh L, et al: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609-4614, 2002
12. Chiorazzi N, Ferrarini M: B cell chronic lymphocytic leukemia: Lessons Learned from studies of the B cell antigen receptor. Annu Rev Immunol 21:841-894, 2003
13. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
14. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003
15. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
16. Damle RN, Ghiotto F, Valetto A, et al: B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99:4087-4093, 2002
17. Davis RE, Brown KD, Siebenlist U, et al: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874, 2001
18. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, et al: Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 10:1833-1840, 1995
19. Dreyling MH, Bullinger L, Ott G, et al: Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 57:4608-4614, 1997
20. Dyer MJ, Oscier DG: The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. Leukemia 16:973-984, 2002
21. Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868, 1998
22. Falini B, Fizzotti M, Pucciarini A, et al: A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95:2084-2092, 2000
23. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
24. Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251, 1997
25. Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755, 2003
26. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002
27. Greiner TC, Moynihan MJ, Chan WC, et al: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996
28. Grogan TM, Lippman SM, Spier CM, et al: Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 71:1157-1160, 1988
29. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
30. Hernandez L, Fest T, Cazorla M, et al: p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351-3359, 1996
31. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002
32. Huang JZ, Sanger WG, Greiner TC, et al: The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285-2290, 2002
33. Iwakoshi NN, Lee AH, Vallabhajosyula P, et al: Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 4:321-329, 2003
34. Jaffe ES, Harris NL, Stein H, et al: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC, 2001
35. Khouri IF, Romaguera J, Kantarjian H, et al: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998
36. Khouri IF, Lee MS, Romaguera J, et al: Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10:1293-1299, 1999
37. Kipps TJ, Carson DA: Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 81:2475-2487, 1993
38. Klein U, Tu Y, Stolovitzky GA, et al: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194:1625-1638, 2001
39. H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002
40. Lanham S, Hamblin T, Oscier D, et al: Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101:1087-1093, 2003
41. Lardelli P, Bookman MA, Sundeen J, et al: Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 14:752-763, 1990
42. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, et al: A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 9:1925-1929, 1994
43. Lin S, Wang W, Wilson GM, et al: Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover. Mol Cell Biol 20:7903-7913, 2000
44. List AF, Spier CM, Miller TP, et al: Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: Relationship to HLA expression and host immunocompetence. Leukemia 7:398-403, 1993
45. Lossos IS, Alizadeh AA, Eisen MB, et al: Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 97:10209-10213, 2000
46. Louie DC, Offit K, Jaslow R, et al: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 86:2892-2899, 1995
47. Orchard J, Ibbotson R, Davis Z, et al: ZAP-70 expression by flow cytometry: A new prognostic marker in CLL. Lancet (in press)
48. Oscier DG, Gardiner AC, Mould SJ, et al: Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177-1184, 2002
49. Pinyol M, Cobo F, Bea S, et al: p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91:2977-2984, 1998
50. Raffeld M, Jaffe ES: bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 78:259-263, 1991
51. Raty R, Franssila K, Joensuu H, et al: Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 69:11-20, 2002
52. Reimold AM, Iwakoshi NN, Manis J, et al: Plasma cell differentiation requires the transcription factor XBP-1. Nature 412:300-307, 2001
53. Rimokh R, Berger F, Bastard C, et al: Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 83:3689-3696, 1994
54. Rosenberg CL, Wong E, Petty EM, et al: PRAD1, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88:9638-9642, 1991
55. Rosenwald A, Alizadeh AA, Widhopf G, et al: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639-1648, 2001
56. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
57. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003
58. Schweighoffer E, Vanes L, Mathiot A, et al: Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 18:523-533, 2003
59. Seto M, Yamamoto K, Iida S, et al: Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 7:1401-1406, 1992
60. Shaffer AL, Rosenwald A, Hurt EM, et al: Signatures of the immune response. Immunity 15:375-385, 2001
61. Shaffer AL, Lin KI, Kuo TC, et al: Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17:51-62, 2002
62. Sherr CJ: D-type cyclins. Trends Biochem Sci 20:187-190, 1995
63. Sherr CJ, Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512, 1999
64. Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2:103-112, 2002
65. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine leaming. Nat Med 8:68-74, 2002
66. Silvestrini R, Costa A, Boracchi P, et al: Cell proliferation as a long-term prognostic factor in diffuse large-cell lymphomas. Int J Cancer 54:231-236, 1993
67. Staudt LM, Brown PO: enomic views of the immune system. GAnn Rev Immunol 18:829-859, 2000
68. Staudt LM: Molecular diagnosis of the hematological cancers. N Engl J Med 348:1777-1785, 2003
69. Stopeck AT, Gessner A, Miller TP, et al: Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 6:3904-3909, 2000
70. Swerdlow SH, Williams ME: From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades. Hum Pathol 33:7-20, 2002
71. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
72. Tobin G, Thunberg U, Johnson A, et al: Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99:2262-2264, 2002
73. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al: Mantle-cell lymphoma: A population-based clinical study. J Clin Oncol 14:1269-1274, 1996
74. Vose JM, Bierman PJ, Weisenburger DD, et al: Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 6:640-645, 2000
75. Weller S, Faili A, Garcia C, et al: CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci USA 98:1166-1170, 2001
76. Wiestner A, Rosenwald A, Barry TS, et al: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes inferior clinical outcome and distinct gene expression profile. Blood 101:4944-4951, 2003
77. William J, Euler C, Christensen S, et al: Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 297:2066-2070, 2002
78. Wilson WH, Grossbard ML, Pittaluga S, et al: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 99:2685-2693, 2002
79. Withers DA, Harvey RC, Faust JB, et al: Characterization of a candidate bcl-1 gene. Mol Cell Biol 11:4846-4853, 1991
80. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B Cell lymphoma. Proc Natl Acad Sci USA 100:9991-9996, 2003